A pharmaceutical composition containing ginkgolide b and non-peptide thrombin inhibitors and its preparation method and application

A technology of ginkgolide and composition, which is applied in the field of pharmaceutical composition containing ginkgolide B, can solve the problems of small side effects, high price, and high cost, and achieve the effects of reducing dosage, clear mechanism of action, and reducing dosage

Active Publication Date: 2019-03-15
CHENGDU BAIYU PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Ginkgolide B is the active ingredient extracted from the natural medicine Ginkgo biloba. It has few side effects and strong activity. It is the strongest platelet activating factor antagonist found so far. It can be used for anticoagulation, but the price is high and it is not used clinically. the cost is too high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition containing ginkgolide b and non-peptide thrombin inhibitors and its preparation method and application
  • A pharmaceutical composition containing ginkgolide b and non-peptide thrombin inhibitors and its preparation method and application
  • A pharmaceutical composition containing ginkgolide b and non-peptide thrombin inhibitors and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Ginkgolide B10 parts

[0028] Dabigatran etexilate 200 parts

[0029] Pharmaceutically acceptable conventional excipients

[0030] After the above-mentioned raw materials are mixed, a pharmaceutically acceptable conventional auxiliary material is added to prepare a pill according to a conventional process.

Embodiment 2

[0032] Ginkgolide B5 parts

[0033] Dabigatran etexilate 400 parts

[0034] Pharmaceutically acceptable conventional excipients

[0035] After the above raw materials are mixed, add pharmaceutically acceptable conventional auxiliary materials and prepare capsules or soft capsules according to conventional techniques.

Embodiment 3

[0037] Ginkgolide B20 parts

[0038] Dabigatran etexilate 50 parts

[0039] Pharmaceutically acceptable conventional excipients

[0040] After the above-mentioned raw materials are mixed, add conventional pharmaceutically acceptable auxiliary materials and prepare tablets according to conventional processes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition containing ginkgolide B. The pharmaceutical composition comprises the ginkgolide B and pseudo-peptide thrombin inhibitor. The invention further provides a preparation method and application of the pharmaceutical composition. The pharmaceutical composition has the advantages that the ginkgolide B and the pseudo-peptide thrombin inhibitor are combined to achieve a synergic effect, and the pharmaceutical composition is excellent in anticoagulation effect, low in side effect and promising in clinical application prospect; the pharmaceutical composition is novel in prescription, simple in component, clear in action mechanism, evident in curative effect, less prone to tolerance generating and capable of achieving large-scale industrial production.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing ginkgolide B. Background technique [0002] Dabigatran etexilate is the most advanced new generation of oral anticoagulant drugs direct thrombin inhibitors (DTIs), chemical name: β-alanine, N-[[2-[[[4-[[[(hexyloxy Base)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyrimidine-, ethyl ester, methanesulfonate salt. Chemical Molecular Formula: C 34 h 41 N 7 o 5 CH 4 o 3 S, for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Prevention of stroke and systemic embolism (SEE) in adults with nonvalvular AF who have one or more of the following risk factors: previous stroke, transient ischemic attack, or systemic embolism; left ventricular ejection fraction <40 %; Symptomatic heart failure, New York Heart Association (NYHA) cardiac function class ≥ 2; age ≥ 75 years; age ≥ 65 years, and any of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4439A61K45/00A61P7/02A61K31/365
Inventor 孙毅
Owner CHENGDU BAIYU PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap